Clinical trial · Interventional
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
Glucose Metabolic Response by PET/CT to Sarcoma Treatments
NCT00335751CI-TRIAL-00046328completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| positron emission tomography computed tomography (PET/CT) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- positron emission tomography computed tomography (PET/CT)
- description
- The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
- interventionNames
- Procedure: positron emission tomography computed tomography (PET/CT)
Primary outcomes (1)
- measure
- Determine whether device that combines fludeoxyglucose ^18F positron-emission tomography (FDG-PET) and CT scanning (FDG-PET/CT) can accurately locate and determine disease in patients who are undergoing treatment for bone or soft tissue sarcoma.
- timeFrame
- 6 months
Secondary outcomes (4)
- measure
- •Determine whether FDG-PET/CT scanning is effective in evaluating the response of sarcoma to treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed bone or soft tissue sarcoma * Scheduled to undergo treatment (i.e., chemotherapy and/or radiotherapy) for sarcoma * Negative pregnancy test * Fertile patients must use effective contraception * Not claustrophobic * Able to lie supine for 1 hour * Patients with diabetes mellitus allowed provided serum glucose levels ≤ 200 mg/dL Exclusion Criteria: * pregnant * other malignancies within the past 5 years (except completely resected cervical or nonmelanoma skin cancer) unless the malignancy was curatively treated and is at low risk for recurrence
References
Publications (0)
Data not yet available
No reference posted for this study.